Navigation Links
vProtect(TM) Luminal Shield Stabilizes Vulnerable Plaque
Date:6/1/2009

Six-Month Follow-Up Shows Reduced Stenosis, Healthy Endothelial Regrowth in Vessel Treated Proactively for Vulnerable Plaque

DOYLESTOWN, Pa., June 1 /PRNewswire/ -- Six months after placement of a vProtect(TM) Luminal Shield to treat a "vulnerable" plaque, a follow-up exam revealed reduced plaque burden and reduced stenosis in the target vessel. The exam was part of the SECRITT I trial, a randomized study designed to evaluate the vProtect(TM) Luminal Shield as a prophylactic treatment for non-flow-limiting vulnerable plaques. The SECRITT I trial is sponsored and conducted by Erasmus University in Rotterdam. The 6-month follow-up exam was performed on May 20 by an interventional cardiology team led by Professor Patrick Serruys, the principal investigator for the SECRITT I study. Evelyn Regar, MD, PhD moderated the case at the EuroPCR congress in Barcelona. The vProtect(TM) Luminal Shield is manufactured by Prescient Medical, which plans to pursue a vulnerable plaque indication in the future.

The patient, a 75-year-old woman, was treated six months earlier for a culprit lesion in the left anterior descending coronary artery. At that time the SECRITT investigators, using a combination of imaging techniques, also located a vulnerable plaque in the patient's left circumflex artery. The lesion was unremarkable by angiography (37% diameter stenosis); such lesions are usually not treated, even though vulnerable plaques are prone to rupture with potentially fatal consequences. A 3.5 mm vProtect(TM) Luminal Shield was placed in the vessel (reference vessel diameter 2.74 mm), resulting in a post-procedural stenosis of 30%.

The 6-month angiographic follow-up exam was performed per study protocol using a variety of imaging techniques: multi-slice CT, intravascular ultrasound (IVUS), IVUS-virtual histology (IVUS-VH), angiography, and optical coherence tomography (OCT). Additional details on the SECRITT I
'/>"/>

SOURCE Prescient Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield
2. Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial
3. Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
4. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
5. Doctors Urge Precaution to Shield Against Swine Flu
6. NanoVibronix Receives Wound Healing Indications in Europe for its PainShield(TM) Device
7. Blue Cross Blue Shield Of Michigan Battles Sluggish Economy With Diverse Product Lineup
8. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
9. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
10. Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis
11. FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... – Small Cap IR issues report. Recently, Arrayit Corporation ... blood card technology to Vivos, Global Genome Vault, the ... an impervious, impenetrable and permanent DNA storage vault, able ... Earth, a safe and secure nuclear blast-proof, underground shelter ... rapid collection, separation, drying and storage of human genomic ...
(Date:6/30/2015)... N.C. , June 30, 2015  Marken, the ... to the life sciences industry, has been granted permission ... patient shipment of clinical drug product in Korea.  This ... South Korea to continue receiving their clinical ... System (MERS). The emergency was caused by ...
(Date:6/30/2015)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announces ... of StockholdersWhen:Tuesday, June 30 at 5:10 p.m. ET / ... log onto our website listed above.   ... event, a replay of the webcast will be available ... ABOUT ISIS PHARMACEUTICALS, INC. Isis is ...
Breaking Medicine Technology:Small Cap IR - Empowering the Age of Genetic Enlightenment 2Marken Delivers Direct To Patients During MERS Outbreak 2Marken Delivers Direct To Patients During MERS Outbreak 3Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting 2Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting 3
... Feb. 23 MAP,Pharmaceuticals, Inc. (Nasdaq: ... 3 clinical trial of Unit Dose Budesonide (UDB) ... The Company announced that the clinical,trial did not ... by,changes from baseline in nighttime and daytime composite ...
... BCRX ) today announced that the full ... peramivir in patients hospitalized for influenza was presented by ... Professor, Divisions of Infectious Diseases and Organ Transplantation at ... the XI International Symposium on Respiratory Viral Infections taking ...
Cached Medicine Technology:MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 2MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 3Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 2Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 3Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 4Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 5
(Date:6/30/2015)... , ... June 30, 2015 , ... According to a ... 2007 to 2013 while heroin-related deaths more than tripled in the same period—leading a ... Novus Medical Detox Center , a leading Florida-based drug treatment facility, asserts that ...
(Date:6/30/2015)... ... 30, 2015 , ... ADVOCATE, the premier provider of radiology ... exclusive billing agreements with Jackson Radiology Associates in Jackson, TN. , ... of billing process software functionality called Experience Based Technology (EBTTM). EBTTM improves ...
(Date:6/30/2015)... ... ... On June 26, 2015, Harper’s Bazaar Magazine in an article titled “5 ... not expect to cause acne flare-ups. The list includes pillowcases, cell phones, ... are clogged pores and bacteria and each of the named triggers unexpectedly creates a ...
(Date:6/30/2015)... Jacksonville, FL (PRWEB) , ... June 30, 2015 ... ... in Jacksonville, reported today it has more than doubled the size of its ... , The center’s medical staff -- which includes physicians, nurse practitioners and physician ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... 26th Annual Alzheimer's Association of Colorado's Education Symposium on November 9, 2015 at ... is honored to host a conversation with Kim and Ashley Campbell, the wife ...
Breaking Medicine News(10 mins):Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 2Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 3Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 4Health News:ADVOCATE Wins Billing Agreements with Jackson Radiology Associates 2Health News:A List of 5 Surprising Acne Triggers and the Latest Acne Treatment Options 2Health News:Lakeview Health, a Nationally Recognized Drug Rehabilitation Center in Florida, Doubles Size of Medical Staff 2Health News:Family of Singer Glen Campbell to Discuss Living with Dementia at the Alzheimer's Association of Colorado's 26th Annual Education Symposium 2
... to Focus on G-Protein Coupled Receptors, BERWYN, ... discovery,company focused on developing pharmaceutical products targeting G-protein,coupled ... $24 million,Series A financing. Alta Partners and Healthcare ... syndicate that included New Enterprise Associates and,Polaris Venture ...
... GAINESVILLE, Fla., March 5 In a strange ... new, non-surgical infertility treatment started,reporting unusual side-effects: increased ... reproductive tract adhesions, caused,unexpected results in some patients ... physical therapist Belinda Wurn. (see, http://www.clearpassage.com ), ...
... have discovered an Antarctic fish species that adopts a ... week in the journal PLoS ONE, the online journal ... Antarctic Survey (BAS) and the University of Birmingham reveal, ... coriiceps effectively puts itself on ice to survive the ...
... Calif., March 5 "I have never,experienced greater satisfaction ... cells.", The quote, from Greg Smith, CEO, Mountain ... the storage of umbilical cord blood by,CorCell, Philadelphia, Pa., ... Mr. Smith continues: "The thought of possibly protecting ...
... entered into by,Airborne Health, Inc. - the maker of ... In that settlement, Airborne,Health, Inc. agreed to pay approximately ... California. The settlement has been reported in the,national media ... Airborne Health,Inc., But there is more to the ...
... Secretary of Health,Dr. Calvin B. Johnson met with ... to discuss Governor Edward G. Rendell,s plan to ... of uninsured adults,through his "Cover All Pennsylvanians" proposal., ... help prevent disease,successfully manage chronic diseases such as ...
Cached Medicine News:Health News:Trevena, Inc. Announces $24 Million Series A Financing 2Health News:Trevena, Inc. Announces $24 Million Series A Financing 3Health News:Surprise Orgasms Baffle Women Undergoing New Infertility Treatment 2Health News:Hibernation-like behavior in Antarctic fish -- on ice for winter 2Health News:Greatest Satisfaction Preserving Granddaughter's Cord Blood Stem Cells 2Health News:Information About The Airborne Health, Inc. Settlement, and Other Ongoing Litigation Alleging False and Deceptive Marketing Of Airborne(R) 2Health News:Information About The Airborne Health, Inc. Settlement, and Other Ongoing Litigation Alleging False and Deceptive Marketing Of Airborne(R) 3Health News:Health Secretary Stops in Erie County to Call for Health Insurance for all Pennsylvanians 2
... are an ophthalmologic medical device designed for ... -1.00 to -3.00 diopters.* When placed in ... central optical zone, the product reshapes the ... is composed of two prescription inserts, each ...
... is our most affordable basic centrifuge. The 614 is ... 614 is also the quietest small lab centrifuge on ... up to six (6) test tubes up to 15ml ... lid safety switch and is UL/CSA compliant. ...
... is a simple one, help physicians serve ... image, the physician is provided with significantly ... structures. This technical accomplishment is combined with ... The device features: ...
... Contour Eyelid Implants feature a proprietary ... of the ocular globe. The Contour ... in the eyelid because the tapered lower ... lower profile. Surfaces and edges of the ...
Medicine Products: